Essential Partners
ENTA icon

Essential Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Essential Partners’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.01K Hold
380
– – ﹤0.01% 1506
2026
Q2 		$5.54K Sell
380
-1,136
-75% -$15.3K ﹤0.01% 1500
2026
Q1 		$19.1K Hold
1,516
– – 0.01% 949
2025
Q4 		$23.9K Hold
1,516
– – 0.01% 842
2025
Q3 		$18.1K Sell
1,516
-57
-4% -$455 0.01% 924
2025
Q2 		$11.9K Buy
+1,573
New +$9.46K ﹤0.01% 800

Other funds holding ENTA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Essential Partners's ENTA Position: Q3 2026 in Review

Essential Partners held its Enanta Pharmaceuticals (ENTA) position steady in Q3 2026 at 380 shares worth $5.01K. The position accounts for ﹤0.01% of the portfolio, ranked #1506.

Essential Partners first reported a position in ENTA in Q2 2025 and has held it in 6 quarters since. The position peaked at $23.9K in Q4 2025. 9 funds tracked by Wall St. Rank hold ENTA as of Q3 2026.

  • Essential Partners held 380 shares of Enanta Pharmaceuticals worth $5.01K as of Q3 2026.
  • Essential Partners left its Enanta Pharmaceuticals share count unchanged in Q3 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1506 holding.
  • Essential Partners first reported a position in Enanta Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Enanta Pharmaceuticals position peaked at $23.9K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.